Author

U. Martin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Bioengineering· 1 Cell Biology· 1 Evolutionary Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Organism:human· 7 Assay:bulk RNA-seq· 5 Research Focus:cell type annotation· 4 Research Focus:host-pathogen & immune response· 4 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

R. Olmer· 6 shared S. Ciesek· 3 shared A. Richter· 2 shared C. Drosten· 2 shared C. Goffinet· 2 shared D. Bojkova· 2 shared D. Jonigk· 2 shared D. Niemeyer· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

R. Olmer

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Cell therapy with human iPSC-derived cardiomyocyte aggregates leads to efficient engraftment and functional recovery after myocardial infarction in non-human primates

I. Gruh, A. Martens, S. Cebotari, A. Schrod, A. Haase, C. Halloin, W. Triebert, T. Goecke, M. Arar, K. Hoeffler, P. Frank, K. Lampe, A. Moussavi, V. Fricke, N. Kriedemann, , U. Martin

This study transplants human iPSC-derived cardiomyocyte aggregates into non-human primates with myocardial infarction, showing efficient engraftment and functional recovery with lower cell doses than previous single-cell approaches.

bioRxiv · Dec 31, 2023 · PreprintCell Biology

NRF2 activators inhibit influenza A virus replication by interfering with nucleo-cytoplasmic export of viral RNPs in an NRF2-independent manner

F. H. Waqas, M. Shehata, W. A. M. Elgaher, A. Lacour, N. Kurmasheva, F. Begnini, A. E. K. E. Kiib, J. Dahlmann, C. Chen, T. B. Poulsen, S. Merkert, U. Martin, R. Olmer, D. Olagnier, A. Hirsch, , F. Pessler

This paper shows NRF2 activators inhibit influenza A virus by blocking nuclear export of viral RNPs, independent of NRF2 signaling, through interaction with XPO1 and KEAP1.

bioRxiv · Jun 11, 2023Microbiology

Primary Ciliary Dyskinesia patient specific hiPSC-derived airway epithelium in Air Liquid Interface culture recapitulates disease specific phenotypes in vitro

L. von Schledorn, D. P. Martin, N. Cleve, J. Zoellner, D. Roth, B. O. Staar, J. Hegermann, F. Ringshausen, J. C. Nawroth, U. Martin, R. Olmer

The paper develops an in vitro model of PCD using hiPSC-derived airway epithelium that recapitulates disease-specific phenotypes.

bioRxiv · Apr 25, 2023 · PreprintBioengineering

Pharmacological inhibition of bromodomain and extra-terminal proteins induces NRF-2-mediated inhibition of SARS-CoV-2 replication and is subject to viral antagonism

B. Mhlekude, D. Postmus, J. Weiner, S. Stenzel, F. J. Zapatero-Belinchon, R. Olmer, J. Jansen, A. Richter, J. Heinze, N. Heinemann, B. Muhlemann, S. Schroeder, T. C. Jones, M. A. Muller, C. Drosten, , C. Goffinet

This study shows JQ-1 inhibits SARS-CoV-2 replication via NRF-2 activation but is counteracted by viral antagonism, leading to transient antiviral effects.

bioRxiv · Sep 22, 2022 · PreprintMicrobiology

Omicron-induced interferon signalling prevents influenza A virus infection

D. Bojkova, M. Bechtel, T. Rothenburger, J. D. Kandler, L. Hayes, R. Olmer, U. Martin, D. Jonigk, S. Ciesek, M. N. Wass, M. Michaelis, J. Cinatl

This study shows Omicron variants induce interferon responses in human cells, protecting against influenza A virus super-infection, while Delta does not.

bioRxiv · Sep 6, 2022 · PreprintMicrobiology

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

D. Bojkova, P. Reus, L. Panosch, M. Bechtel, T. Rothenburger, J. Kandler, A. Pfeiffer, J. U. Wagner, M. Shumliakivska, S. Dimmeler, R. Olmer, U. Martin, F. Vondran, T. Toptan, F. Rothweiler, , J. Cinatl

This study develops a phenotypic screening platform using caspase 3/7 activity to identify antiviral compounds against SARS-CoV-2, including novel candidates and combinations.

bioRxiv · Jul 17, 2022Pharmacology & Toxicology

Post-entry, spike-dependent replication advantage of B.1.1.7 and B.1.617.2 over B.1 SARS-CoV-2 in an ACE2-deficient human lung cell line

D. Niemeyer, S. Schroeder, K. Friedmann, F. Weege, J. Trimpert, A. Richter, S. Stenzel, J. Jansen, J. Emanuel, J. Kazmierski, F. Pott, L. M. Jeworowski, R. Olmer, M.-C. Jaboreck, B. Tenner, , C. Drosten

The paper shows that B.1.1.7 and B.1.617.2 SARS-CoV-2 variants have a replication advantage over B.1 in ACE2-deficient lung cells, suggesting reliance on alternative cellular factors.

bioRxiv · Oct 20, 2021 · PreprintMicrobiology

An early cell shape transition drives evolutionary expansion of the human forebrain

S. Benito-Kwiecinski, S. L. Giandomenico, M. Sutcliffe, E. S. Riis, P. Freire-Pritchett, I. Kelava, S. Wunderlich, U. Martin, G. A. Wray, M. A. Lancaster

The paper uses cerebral organoids to show that a delayed cell shape transition in human neuroepithelial cells drives brain expansion compared to apes.

bioRxiv · Jul 4, 2020Evolutionary Biology